These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19912095)

  • 41. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.
    Gortner L
    Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860
    [No Abstract]   [Full Text] [Related]  

  • 42. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC; Long SS;
    Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
    Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
    Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
    [No Abstract]   [Full Text] [Related]  

  • 44. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Indications and prescription modalities of palivizumab in neonates].
    Guillois B
    Arch Pediatr; 2007 Sep; 14 Suppl 1():S16-23. PubMed ID: 17939952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Respiratory Syncytial Virus Bronchiolitis in Children.
    Smith DK; Seales S; Budzik C
    Am Fam Physician; 2017 Jan; 95(2):94-99. PubMed ID: 28084708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics).
    Canfield SD; Simoes EA
    Pediatr Ann; 1999 Aug; 28(8):507-14. PubMed ID: 10483596
    [No Abstract]   [Full Text] [Related]  

  • 49. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
    Oz-Alcalay L; Ashkenazi S; Glatman-Freedman A; Weisman-Demri S; Lowenthal A; Livni G
    Isr Med Assoc J; 2019 Feb; 21(2):110-115. PubMed ID: 30772962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pediatric case management for respiratory syncytial virus outcomes.
    Rieve JA
    Case Manager; 2002; 13(2):32-4. PubMed ID: 11901367
    [No Abstract]   [Full Text] [Related]  

  • 52. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Respiratory syncytial virus].
    Seidenberg J
    Internist (Berl); 2019 Nov; 60(11):1146-1150. PubMed ID: 31486858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Palivizumab: The Effects of Prophylactic Immunization on the Occurrence of Infections Caused by the Respiratory Syncytial Virus.
    Raguz MJ; Brzica J; Grgic I
    Klin Padiatr; 2017 Sep; 229(5):281-285. PubMed ID: 28946159
    [No Abstract]   [Full Text] [Related]  

  • 55. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
    Moore HC; de Klerk N; Richmond PC; Fathima P; Xu R; Keil AD; Snelling TL; Strunk T
    J Pediatr; 2019 Nov; 214():121-127.e1. PubMed ID: 31378522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
    Rodríguez SP; Fariña D; Bauer G
    Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.